| Literature DB >> 8809165 |
D L Romero1, R A Olmsted, T J Poel, R A Morge, C Biles, B J Keiser, L A Kopta, J M Friis, J D Hosley, K J Stefanski, D G Wishka, D B Evans, J Morris, R G Stehle, S K Sharma, Y Yagi, R L Voorman, W J Adams, W G Tarpley, R C Thomas.
Abstract
A novel class of bis(heteroaryl)piperazine (BHAP) analogs which possesses the ability to inhibit NNRTI (non-nucleoside reverse transcriptase inhibitor) resistant recombinant HIV-1 reverse transcriptase (RT) and NNRTI resistant variants of HIV-1 has been identified via targeted screening. Further investigation of the structure-activity relationships of close congeners of these novel (alkylamino)piperidine BHAPs (AAP-BHAPs) led to the synthesis of several compounds possessing the desired phenotype (e.g., activity against recombinant RTs carrying the Y181C and P236L substitutions). Further structural modifications were required to inhibit metabolism and modulate solubility in order to obtain compounds with the desired biological profile as well as appropriate pharmaceutical properties. The AAP-BHAPs with the most suitable characteristics were compounds 7, 15, and 36.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8809165 DOI： 10.1021/jm960158n
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446